Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | HCN4 | Q9Y3Q4 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5532770 | 0.79 | ALDH1A1 (0.46) | ALDH1A1KDM4EMAPTPOLBSMN1; SMN2 | |
| SCHEMBL5502867 | 0.76 | OPRM1 (0.45) | ALDH1A1KDM4ECYP3A4CYP2D6 | |
| SCHEMBL5507150 | 0.76 | ALDH1A1 (0.44) | ALDH1A1KDM4EMAPTPOLBSMN1; SMN2 | |
| SCHEMBL5521172 | 0.75 | ALDH1A1 (0.46) | ALDH1A1KDM4EMAPTPOLBSMN1; SMN2 | |
| SCHEMBL14677512 | 0.75 | CYP3A4 (0.45) | ALDH1A1LMNACYP3A4CYP2D6CYP2C9 | |
| SCHEMBL1221046 | 0.75 | CYP3A4 (0.48) | ALDH1A1MAPTCYP3A4CYP2D6CYP2C9 | |
| SCHEMBL1189507 | 0.72 | ALDH1A1 (0.49) | ALDH1A1KDM4ECYP3A4CYP2D6CYP2C9 | |
| SCHEMBL3892538 | 0.70 | THRB (0.41) | THRBLMNAMAPTPOLBHCN4 | |
| SCHEMBL20746152 | 0.70 | P2RX7 (0.60) | ALDH1A1KDM4ETHRBLMNAMAPT | |
| SCHEMBL3887165 | 0.69 | ALDH1A1 (0.46) | ALDH1A1KDM4ECYP3A4CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7572792-B2 | Azetidine glycine transporter inhibitors | MERCK & CO., INC. (US) | 2009-08-11 | — | — | US | disclosed |
| US-20080021010-A1 | Azetidine Glycine Transporter Inhibitors | MERCK SHARP & DOHME LIMITED (GB) | 2008-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080021010-A1 | Azetidine Glycine Transporter Inhibitors | SLC1A2, SLC18A2, SLC1A1 | ALDH1A1 1719/4885KDM4E 2949/4885THRB 1410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.